Biocon 执行董事长称，AI 在临床试验中的应用是“圣杯”
Biocon Chair: AI in Clinical Trials Is the Holy Grail
Biocon 执行董事长 Kiran Mazumdar-Shaw 表示，AI 在临床试验中预测安全性和有效性、缩短耗时且昂贵的试验，是这项技术的“圣杯”。她还称，生物药专利到期潮为扩大价格可负担的癌症生物类似药业务、提升 Biocon 的全球排名提供了重要空间。
Oct 15th, 2026
Biocon Chair: AI in Clinical Trials Is the Holy Grail
Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg New Economy Forum in New Delhi, Mazumdar-Shaw added that while AI accelerates molecular discovery, the true "holy grail" is using the technology to abbreviate long, expensive clinical trials by predicting safety and efficacy.
来源：Bloomberg Markets · bloomberg.com